Evidence map›Paper›PMID 36691796›Full record

ArticleJournal of the International AIDS Society2023

Incident HIV acquisition among pregnant women in Botswana: findings from the Tsepamo birth outcomes surveillance study.

Aamirah Mussa, Gloria Katuta Mayondi, Modiegi Diseko, Judith Mabuta, Mompati Mmalane, Joseph Makhema, Shahin Lockman, Chelsea Morroni, Roger Shapiro, Rebecca Zash

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Aamirah MussaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.ORCID 0000-0001-9152-5686
Gloria Katuta MayondiBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Modiegi DisekoBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Judith MabutaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Mompati MmalaneBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph MakhemaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Chelsea MorroniBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Roger ShapiroBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rebecca ZashBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.ORCID 0000-0001-5707-421X
Botswana Harvard AIDS Institute Partnership · BWBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USHarvard University · USMRC Centre for Reproductive Health · GB

Funding

Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART RegimensP01HD107670 · NICHD · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2021 to 2025
$6.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Botswana Birth Outcomes Surveillance ExtensionR01HD095766 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2018 to 2022
$3.3M
Birth Outcomes Surveillance in BotswanaR01HD080471 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2014 to 2018
$2.6M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral TherapyK23HD088230 · NICHD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZASH, REBECCA MARIE · 2017 to 2021
$820k
FIC NIH HHS D43 TW009610NIAID NIH HHS K24 AI131928NICHD NIH HHS K23 HD088230NICHD NIH HHS P01 HD107670NICHD NIH HHS R01 HD080471NICHD NIH HHS R01 HD095766
6 · The paper itself

Abstract

introductionIn Botswana, where almost all pregnant women known to have HIV receive antiretroviral therapy, a large proportion of vertical HIV transmission may occur among women with incident undiagnosed HIV infection during pregnancy. Botswana guidelines recommend repeat HIV testing every 3 months in pregnancy, with at least one test in the third trimester. We evaluated the rate of repeat HIV testing, calculated HIV incidence during pregnancy and estimated missed seroconversions.

methodsIn the Botswana Tsepamo Study, we abstracted HIV test dates and results from obstetric records of all women who delivered at maternity wards in 18 communities between 7th May 2017 and 20th August 2021. We defined seroconversion as an initial negative/indeterminate HIV test in pregnancy followed by a positive test during pregnancy/at delivery. The incidence rate (IR) of seroconversion was calculated among women with > = 2 known test dates. Missed seroconversions were estimated among women without a test in the third trimester by applying the IR to the time after the last HIV test until delivery.

resultsAmong 103,529 women delivering in the study period testing negative at the first test and with known conception and HIV test dates, 29,085 (28%) were tested in one trimester of pregnancy, 73,156 (71%) were tested in ≥ 2 trimesters of pregnancy and 9628 (9%) had a test in all trimesters. A total of 78,162 (75%) women had a third-trimester test. There were 223 seroconversions (2.58/1000 pregnancies, 0.26%) among those with ≥ 2 known HIV test dates, yielding an IR of 0.69/100 person-years. Among 25,289 women who did not have a test in the third trimester, we estimate approximately 58 seroconversions may have been missed during pregnancy due to a lack of repeat testing. Factors associated with seroconversion during pregnancy included younger age, less education and not being married.

conclusionsMore than two-thirds of women had repeat HIV testing in pregnancy and HIV incidence was low. However, an estimated 21% of seroconversions in pregnancy were likely missed due to a lack of re-testing. To reach the goal of zero new paediatric HIV infections, Botswana will need to intensify repeat HIV testing in the third trimester of pregnancy.

Indexed as

HIV InfectionsHIV SeropositivityPregnancy Complications, InfectiousBotswanaChildFemaleHumansInfectious Disease Transmission, VerticalPregnancyPregnant PeopleAfricaBotswanaHIVpregnancyseroconversionvertical transmission

Identifiers

PMID36691796
PMCPMC9871722
OpenAlexW4317871078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.